Tags

Type your tag names separated by a space and hit enter

Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
J Clin Microbiol. 2021 04 20; 59(5)JC

Abstract

In this study, we comprehensively analyzed multispecific antibody kinetics of different immunoglobulins in hospitalized patients with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Three hundred fifty-four blood samples longitudinally obtained from 81 IgG-seroconverting progressed coronavirus disease 2019 (CoVID-19) patients were quantified for spike 1 (S1), S2, and nucleocapsid protein (NCP)-specific IgM, IgA, IgG, and total Ig antibodies using a microarray, 11 different enzyme-linked immunosorbent assays (ELISAs)/chemiluminescence immunoassays (CLIAs), and 1 rapid test by seven manufacturers. The assays' specificity was assessed in 130 non-CoVID-19 pneumonia patients. Using the microarray, NCP-specific IgA and IgG antibodies continuously displayed higher detection rates during acute CoVID-19 than S1- and S2-specific ones. S1-specific IgG antibodies, however, reached higher peak values. Until the 26th day post-symptom onset, all patients developed IgG responses against S1, S2, and NCP. Although detection rates by ELISAs/CLIAs generally resembled those of the microarray, corresponding to the target antigen, sensitivities and specificities varied among all tests. Notably, patients with more severe CoVID-19 displayed higher IgG and IgA levels, but this difference was mainly observed with S1-specific immunoassays. In patients with high SARS-CoV-2 levels in the lower respiratory tract, we observed high detection rates of IgG and total Ig immunoassays with a particular rise of S1-specific IgG antibodies when viral concentrations in the tracheal aspirate subsequently declined over time. In summary, our study demonstrates that differences in sensitivity among commercial immunoassays during acute SARS-CoV-2 infection are only partly related to the target antigen. Importantly, our data indicate that NCP-specific IgA and IgG antibodies are detected earlier, while higher S1-specific IgA antibody levels occur in severely ill patients.

Authors+Show Affiliations

Center for Virology, Medical University of Vienna, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria.Kaiser-Franz-Josef Hospital, Clinic Favoriten, 4th Medical Department, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria.Center for Virology, Medical University of Vienna, Vienna, Austria lukas.weseslindtner@meduniwien.ac.at.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33602698

Citation

Semmler, Georg, et al. "Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection By a Microarray and Twelve Other Immunoassays." Journal of Clinical Microbiology, vol. 59, no. 5, 2021.
Semmler G, Traugott MT, Graninger M, et al. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. J Clin Microbiol. 2021;59(5).
Semmler, G., Traugott, M. T., Graninger, M., Hoepler, W., Seitz, T., Kelani, H., Karolyi, M., Pawelka, E., Aragón de La Cruz, S., Puchhammer-Stöckl, E., Aberle, S. W., Stiasny, K., Zoufaly, A., Aberle, J. H., & Weseslindtner, L. (2021). Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. Journal of Clinical Microbiology, 59(5). https://doi.org/10.1128/JCM.02890-20
Semmler G, et al. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection By a Microarray and Twelve Other Immunoassays. J Clin Microbiol. 2021 04 20;59(5) PubMed PMID: 33602698.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. AU - Semmler,Georg, AU - Traugott,Marianna Theresia, AU - Graninger,Marianne, AU - Hoepler,Wolfgang, AU - Seitz,Tamara, AU - Kelani,Hasan, AU - Karolyi,Mario, AU - Pawelka,Erich, AU - Aragón de La Cruz,Sara, AU - Puchhammer-Stöckl,Elisabeth, AU - Aberle,Stephan Walter, AU - Stiasny,Karin, AU - Zoufaly,Alexander, AU - Aberle,Judith Helene, AU - Weseslindtner,Lukas, Y1 - 2021/04/20/ PY - 2020/11/12/received PY - 2021/02/17/accepted PY - 2021/2/20/pubmed PY - 2021/5/14/medline PY - 2021/2/19/entrez KW - ELISA KW - IgA KW - SARS KW - SARS-CoV-2 KW - antibodies KW - coronavirus KW - immunoassay KW - microarray JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 59 IS - 5 N2 - In this study, we comprehensively analyzed multispecific antibody kinetics of different immunoglobulins in hospitalized patients with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Three hundred fifty-four blood samples longitudinally obtained from 81 IgG-seroconverting progressed coronavirus disease 2019 (CoVID-19) patients were quantified for spike 1 (S1), S2, and nucleocapsid protein (NCP)-specific IgM, IgA, IgG, and total Ig antibodies using a microarray, 11 different enzyme-linked immunosorbent assays (ELISAs)/chemiluminescence immunoassays (CLIAs), and 1 rapid test by seven manufacturers. The assays' specificity was assessed in 130 non-CoVID-19 pneumonia patients. Using the microarray, NCP-specific IgA and IgG antibodies continuously displayed higher detection rates during acute CoVID-19 than S1- and S2-specific ones. S1-specific IgG antibodies, however, reached higher peak values. Until the 26th day post-symptom onset, all patients developed IgG responses against S1, S2, and NCP. Although detection rates by ELISAs/CLIAs generally resembled those of the microarray, corresponding to the target antigen, sensitivities and specificities varied among all tests. Notably, patients with more severe CoVID-19 displayed higher IgG and IgA levels, but this difference was mainly observed with S1-specific immunoassays. In patients with high SARS-CoV-2 levels in the lower respiratory tract, we observed high detection rates of IgG and total Ig immunoassays with a particular rise of S1-specific IgG antibodies when viral concentrations in the tracheal aspirate subsequently declined over time. In summary, our study demonstrates that differences in sensitivity among commercial immunoassays during acute SARS-CoV-2 infection are only partly related to the target antigen. Importantly, our data indicate that NCP-specific IgA and IgG antibodies are detected earlier, while higher S1-specific IgA antibody levels occur in severely ill patients. SN - 1098-660X UR - https://www.unboundmedicine.com/medline/citation/33602698/Assessment_of_S1__S2__and_NCP_Specific_IgM_IgA_and_IgG_Antibody_Kinetics_in_Acute_SARS_CoV_2_Infection_by_a_Microarray_and_Twelve_Other_Immunoassays_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=33602698 DB - PRIME DP - Unbound Medicine ER -